**Name of journal: World Journal of Nephrology**

**ESPS Manuscript NO: 13034**

**Columns: Case Report**

**Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report**

Vigil D *et al*. Nephrogenic diabetes insipidus triggered by HHS

Darlene Vigil, Kavitna Ganta, Yijuan Sun, Richard I Dorin, Antonios H Tzamaloukas, Karen S Servilla

**Darlene Vigil,** **Yijuan Sun, Antonios H Tzamaloukas, Karen S Servilla,** Nephrology Section, Medicine Service, Raymond G Murphy Veterans Affairs Medical Center, Albuquerque, NM 87108, United States

**Kavitna Ganta,** **Yijuan Sun, Richard I Dorin,** **Antonios H Tzamaloukas, Karen S Servilla,** Nephrology Division, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87122, United States

**Richard I Dorin,** Endocrinology Section, Medicine Service, Raymond G Murphy Veterans Affairs Medical Center, Albuquerque, NM 87108, United States

**Author contributions:** Vigil D and Ganta K contributed equally to this work; Vigil D and Ganta K were responsible for parts of the bibliographic search and of the first draft of the report; Sun Y and Dorin RI made critical changes in the manuscript; Tzamaloukas AH assisted in the bibliographic search and wrote parts of the original report; Servilla KS conceived the work and made critical changes in the manuscript.

**Ethics approval:** NA.

**Informed consent:** Approval for this case report was obtained from the human research committee of the Raymond G Murphy VA Medical Center.

**Conflict-of-interest:** The authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Karen S Servilla, MD, Professor** of Medicine, **Nephrologist,** Nephrology Section, Medicine Service, Raymond G Murphy Veterans Affairs Medical Center, 1501 San Pedro SE, Albuquerque, NM 87108, United States. karen.servilla@va.gov

**Telephone:** +1-505-2651711-4846

**Fax:** +1-505-2566442

**Received:** August 2, 2014

**Peer-review started:** August 2, 2014

**First decision:** October 14, 2014

**Revised:** January 7, 2015

**Accepted:** February 9, 2015

**Article in press:**

**Published online:**

**Abstract**

A man with past lithium use for more than 15 years, but off lithium for two years and not carrying the diagnosis of diabetes mellitus or nephrogenic diabetes insipidus (NDI), presented with coma and hyperglycemic hyperosmolar state. Following correction of HHS, he developed persistent hypernatremia accompanied by large volumes of urine with low osmolality and no response to desmopressin injections. Urine osmolality remained < 300 mOsm/kg after injection of vasopressin. Improvement in serum sodium concentration followed the intake of large volumes of water plus administration of amiloride and hydrochlorothiazide. Severe hyperglycemia may trigger symptomatic lithium-induced NDI years after cessation of lithium therapy. Patients with new-onset diabetes mellitus who had been on prolonged lithium therapy in the past require monitoring of their serum sodium concentration after hyperglycemic episodes regardless of whether they do or do not carry the diagnosis of NDI.

**Key words**: Hypertonicity; Hypernatremia; Hyperglycemia; Lithium; Nephrogenic Diabetes insipidus

# © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hyperglycemic coma with large losses of body water may aggravate lithium-induced nephrogenic diabetes insipidus (NDI) which had been asymptomatic and undiagnosed for years after cessation of lithium therapy. The development of conditions leading to loss of water and consciousness in patients who were on long term lithium therapy should trigger surveillance for NDI even when they were asymptomatic in the past.

Vigil D, Ganta K, Sun Y, Dorin RI, Tzamaloukas AH, Servilla KS. Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report. *World J Nephrol* 2015; In press

**INTRODUCTION**

Hypertonicity resulting from excessive losses of body water through the kidneys, the respiratory tract, the skin, or the gastrointestinal tract and/or gain in body solute, causes neurological manifestations that may become life threatening[1,2]. Hypernatremia[3] and hyperglycemia[4] are the two common causes of hypertonicity. Severe hyperglycemia developing on the ground of another condition potentially causing hypernatremia may lead to extreme hypertonicity. We present a patient who developed coma from hyperglycemic hyperosmolar state (HHS) followed by prolonged hypernatremia. Nephrogenic diabetes insipidus (NDI) secondary to chronic lithium intake was diagnosed during the period of hypernatremia. NDI had apparently persisted despite discontinuation of lithium two years prior to the HHS, but had not been diagnosed because of absence of hypernatremia and lack of symptoms of hypertonicity.

**CASE REPORT**

***Calculated values, Summary statistics***

**Calculated values:** Serum tonicity (effective osmolarity), mOsm/L[5] = 2 ×serum sodium concentration ([Na]) + serum glucose concentration ([Glu])/18. Corrected serum sodium concentration [6]: [Na] at hyperglycemia corrected to a [Glu] value of 100 mg/dL by the use of Katz’s[7] correction factor, which computes that a 100 mg/dL rise in [Glu] causes a 1.6 mmol/L depression in [Na]:

[Na]Corrected, mmol/L = [Na] + 0.016x([Glu] -100)

Calculated serum osmolarity, mOsm/L[5] = 2x[Na] + [Glu]/18 + blood urea nitrogen ([BUN])/2.8

**Summary statistics:** Parametric variables are presented as mean ± SD.

***Patient report***

A 58-year-old man with bipolar disorder was admitted with HHS and coma. He had been treated in the past with lithium carbonate for more than 15 years. During that period, serum lithium level was 0.72 ± 0.27 mmol/L (36 determinations) with two values, 1.3 and 1.4 mmol/L above the therapeutic range (0.5-1.2 mmol/L); in 22 determinations, average [Na] and [Glu] values were within the normal range (Table 1), with one [Na] value, at 146 mmol/L, above the upper normal limit of 145 mmol/L and one [Glu] value was in the hyperglycemic range (171 mg/dL); and in 15 determinations urine specific gravity was 1.008 ± 0.004. The urine specific gravity of all five urinalyses obtained in the last five years of this period was ≤ 1.005.

Two years prior to the admission he moved to another town and discontinued the intake of lithium. Two months prior to admission with HHS, he resumed his visits to the outpatient clinics of this hospital after a large left lung mass was diagnosed. Positron emission tomography (PET) study showed a left lung mass 10.9 cm in diameter invading the left main bronchus and the wall of the left pulmonary artery and involvement of several lymph nodes. Lung biopsy revealed squamous cell carcinoma.

He refused treatment for his tumor and opted for palliative management. He did not carry the diagnosis of diabetes mellitus or diabetes insipidus up to that time. During subsequent outpatient visits, progressive hyperglycemia was noted in. Three successive blood samples (Table 1). He refused admission when [Glu] was 809 mg/dL, but was admitted in deep coma three days later. On admission, blood pressure was 147/87 mm Hg and heart rate 87 beats per minute. His mucosae were dry. Initial serum chemistries revealed hyperglycemia and profound hypertonicity (Table 1). In addition, BUN was 67 mg/dL, and serum potassium 3.7 mmol/L, total carbon dioxide 16 mmol/L, creatinine (previously in the normal range) 2.49 mg/dL, phosphorus 6.2 mg/dL, magnesium 4.2 mg/dL, lactate 3.4 mmol/L and calculated serum osmolarity 428.6 mOsm/L. The urine had a specific gravity of 1.016 and contained > 500 mg/dL of glucose, but no acetone. Arterial blood pH was 7.01, PaO2 102 mm Hg (on nasal oxygen supplementation), PaCO2 71 mmHg and calculated bicarbonate 13.2 mEq/L. Chest X-ray showed a large mass in the left lung displacing the trachea to the right and several enlarged noncalcified lymph nodes in both lung fields. These findings were unchanged from those in recent earlier chest X-rays.

He received endotracheal intubation with mechanical ventilation, continuousinfusion of insulin and large volumes of hypotonic saline containing potassium chloride. Large urine output was noted from the onset of treatment. Progressive decline in [Glu] was documented (Table 1). In a blood sample obtained four hours after onset of treatment, BUN was 66 mg/dL, serum creatinine 2.33 mg/dL, and calculated osmolarity 418.2 mOsm/L, while a simultaneously measured serum osmolality was 424 mOsm/kg. Following these measurements he received larger volumes of water in his infusions and through a gastric tube.

Hyperglycemia, hypokalemia, and hyperphosphatemia were corrected by 48 h after initiation of treatment. At that time, BUN was 48 mg/dL and calculated serum osmolarity 451.5 mOsm/L. Serum creatinine and magnesium declined progressively and reached normal levels by 72 h after the start of treatment. He was extubated on the fourth hospital day. However, production of copious volumes of dilute urine, confusion and severe hypernatremia persisted despite the combined administration of up to 400 mL per hour of 5% dextrose intravenously and free water by nasogastric tube. Over the four days following normalization of glycemia, he received progressively larger injections of desmopressin (from 1 to 4 mcg), but post-injection urine osmolality values ranged between 139 and 180 mOsm/kg, while [Na] ranged between 164 and 171 mmol/L, [Glu] between 84 and 281 mg/dL and [Na]Corrected between 164.7 and 173.7 mmol/L.

 On day seven of admission, simultaneous serum and urine measurements revealed the following values: [Na] 161 mmol/L, serum osmolality 330 mOsm/kg, serum vasopressin 4.6 pg/mL, serum lithium undetectable and urine osmolality 279 mOsm/kg. Immediately following these measurements, he received an injection of 5 units of vasopressin. One hour post-injection, urine osmolality was 290 mOsm/kg. Over the next 20 d, his mental status improved slowly, [Glu] ranged between 69 and

304 mg/dL, while [Na]$ $and [Na]Corrected remained elevated (Table 1).

Hypernatremia improved slowly after increase in water intake andadministration of amiloride and hydrochlorothiazide. His last two [Na] values were in the normal range. He left the hospital against medical advice after he was declared competent to make treatment decisions by a Psychiatrist. He was advised to continue the medications for hypernatremia and to have a liberal water intake. Two months later he returned with progressive dyspnea. Computed chest tomography revealed increases in the size of lymph nodes and a large clot in the right pulmonary artery. [Na] was elevated (Table 1). He expired in respiratory failure within 48 h of his last admission. Table 1 shows tonicity values throughout his follow-up.

**DISCUSSION**

This report of a patient developing protracted hypernatremia following treatment of severe HHS illustrates the following clinical points: (1) the level of hypertonicity can become extreme in patients with HHS that remains untreated for several days; (2) Lithium-induced NDI that remained asymptomatic and undiagnosed for years after cessation of lithium therapy can cause severe hypernatremia in patients who encounter difficulties in consuming adequate volumes of water.

Tonicity of the serum is its property to cause osmotic transfers of water into or out of cells suspended in it. [Na] is, in general, an accurate indicator of serum tonicity[8]. Gain in extracellular solutes other than sodium salts, such as glucose, is the main exception to this rule. Hypertonicity in hyperglycemia should be evaluated in two steps: (1) At presentation, the degree of hypertonicity, which results from extracellular accumulation of solute (glucose)[9] and loss of water through osmotic diuresis[10,11], and determines the severity of the presenting clinical manifestations is calculated by the tonicity formula[1,5]; (2) The prescription of the tonicity (*i.e.*, sodium plus potassium concentration) of the replacement solutions should be based on [Na]Corrected[12], reflecting the fact that correction of hyperglycemia without any further changes in the external balances of water and monovalent cations leads to rise in [Na], but decrease in serum effective osmolality[12]. Monitoring of the clinical status and serum chemistries is imperative during treatment of severe HHS[12].

Both serum tonicity and [Na]Corrected were at admission extremely high, indicating profound water deficit, in the patient of this report, who despite infusions of large volumes of hypotonic fluids exhibited subsequently protracted hypernatremia and was eventually diagnosed with NDI by formal testing[13]. Persistently low urine specific gravity values during and after lithium therapy identified lithium as the probable cause of NDI.

Lithium use is associated with a variety of renal functional and structural abnormalities[14,15]. NDI is the most prevalent lithium-induced disorder. Lithium enters the principal cells of the collecting ducts through luminal (apical) epithelial sodium channels (ENaC) and inhibits the signaling pathways that involve glycogen synthase 3-beta causing disruption of the aquaporin-2 structure and function and NDI [16,17].

Amiloride is effective in the prevention and treatment of lithium-induced NDI in part because it is an inhibitor of ENaC, while hydrochlorothiazide affects several transport proteins[18].

Lithium-induced NDI may persist for years after cessation of lithium therapy[19]. Most available reports have found an association between the duration of lithium use and reduced renal concentrating ability supporting a progressive deficit[20]. Movig *et al*[21] reported that 37% of 75 patients receiving lithium developed polyuria (> 3 L/24 h). Polyuria was strongly associated with simultaneous use of serotonergic antidepressants and duration of lithium therapy. Although lithium-induced NDI is often reversible with median duration of therapy (< 6 years), the renal concentrating defect may be permanent after prolonged (> 15 years) therapy with lithium[22]. In large studies with long term follow-up, approximately 15% of patients using lithium demonstrate an irreversible impairment of renal concentration[22]. Several cases of NDI persistence after discontinuation of lithium therapy have been reported[23-29]. Special care is required for patients with this syndrome when they develop medical conditions preventing spontaneous fluid consumption[28].

Another characteristic of lithium-induced NDI is that it may go undiagnosed for years. Patients are able to compensate for this form of NDI, in which the defect in urinary concentration is usually partial, by consuming large fluid volumes. For example the urine volume that is needed for excretion of a solute load of 900 mOsm at a urine osmolality of 300 mOsm/kg is 3 L and can easily be achieved without the development of hypernatremia by patients with normal thirst mechanism.

Lithium-induced NDI can cause severe hypernatremia[30,31] especially after the development of stressful conditions leading to inability of the patients to drink adequate amounts of fluid. We found three reports of four patients on lithium who developed severe hypernatremia secondary to previously undiagnosed lithium-induced NDI in the immediate post- operative period[32-34]. In contrast to these subjects, our patient had stopped lithium intake two years before his admission.

Finally, our patient illustrates the association of manifestations of diabetes mellitus and lithium-induced NDI. Two patients presenting with clinical manifestations of lithium-induced NDI and diabetic ketoacidosis[35] or severe hyperglycemia[36] have been reported. Potential mechanisms of induction of glucose intolerance by lithium were discussed[36]. In addition to the possibility that lithium triggered the development of diabetes mellitus, it is probable that lithium-induced NDI aggravated the water loss secondary to osmotic diuresis in our patient. In osmotic diuresis osmolality values are higher in urine than plasma in all patients except those with diabetes insipidus who exhibit osmolality values lower in urine than in plasma[37]. Thus water losses from osmotic diuresis are comparatively larger and the hypertonic state that ensues is comparatively more severe in the patients with diabetes insipidus.

Lithium-induced NDI that remained asymptomatic and undiagnosed for years after cessation of lithium therapy may cause severe clinical manifestations of hypertonicity during clinical episodes affecting the patients’ access to fluid intake. If these episodes consist of hyperglycemic emergencies, water loss trough combination of hyperglycemic osmotic diuresis and NDI may be massive leading to severe hypertonicity. Patients with severe hyperglycemia who had been on long-term lithium therapy require prolonged attention to their fluid balance after correction of the hyperglycemic episode.

**COMMENTS**

***Case characteristics***

Development of hyperglycemic hyperosmolar state (HHS) with profound coma followed by protracted hypernatremia in a patient who had stopped lithium therapy two years in the past.

***Clinical diagnosis***

Lithium-induced nephrogenic diabetes insipidus (NDI) diagnosed after correction of the HHS by lack of response of the urinary concentration to a formal vasopressin infusion test.

***Differential diagnosis***

Other causes of hypernatremia including central diabetes insipidus, persistent osmotic diuresis, and inadequate water intake were excluded by appropriate testing.

***Laboratory diagnosis***

Extreme hyperglycemia and serum effective osmolarity at presentation was followed by protracted hypernatremia which was shown to be the result of NDI by lack of response of urine osmolality to vasopressin infusion.

***Imaging diagnosis***

Inoperable lung malignant tumor found in chest X-rays, and CT and PET scans.

***Pathological diagnosis***

Squamous cell carcinoma of the lung found on a biopsy of the tumor.

***Treatment***

Insulin infusion, large volumes of hypotonic fluids given parenterally, by nasogastric tube, and later by mouth, amiloride and hydrochlorothiazide for the HHS and later the NDI, refusal of the patient to receive treatment for his lung tumor.

***Related reports***

Reports in the literature suggest that lithium-induced NDI may be permanent after cessation of lithium treatment when the duration of lithium therapy exceeded 15 years, while other reports suggest that lithium-induced NDI may cause severe hyponatremia following episodes of severe hyperglycemia.

***Experience and lessons***

Patients who had been in the past on long-term lithium therapy are at risk of developing severe hypernatremia during episodes that limit their ability to drink water and should have their serum sodium concentration closely monitored during these episodes even if they had not been diagnosed with nephrogenic diabetes insipidus in the past

***Peer-review***

This reviewer thinks that it is worth sharing this case with “prolonged hypernatremia triggered by hyperglycemic hyperosmolar state after discontinuation of lithium therapy” by physicians.

**REFERENCES**

1 **Feig PU**, McCurdy DK. The hypertonic state. *N Engl J Med* 1977; **297**: 1444-1454 [PMID: 337143 DOI: 10.1056/NEJM197712292972608]

2 **Pollock AS**, Arieff AI. Abnormalities of cell volume regulation and their functional consequences. *Am J Physiol* 1980; **239**: F195-F205 [PMID: 7435558]

3 **Adrogué HJ**, Madias NE. Hypernatremia. *N Engl J Med* 2000; **342**: 1493-1499 [PMID: 10816188 DOI: 10.1056/NEJM200005183422006]

4 **Arieff AI**, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. *Medicine (Baltimore)* 1972; **51**: 73-94 [PMID: 5013637 DOI: 10.1097/00005792-197203000-00001]

5 **McCurdy DK**. Hyperosmolar hyperglycemic nonketotic diabetic coma. *Med Clin North Am* 1970; **54**: 683-699 [PMID: 4987277]

6 **Al-Kudsi RR**, Daugirdas JT, Ing TS, Kheirbek AO, Popli S, Hano JE, Gandhi VC. Extreme hyperglycemia in dialysis patients. *Clin Nephrol* 1982; **17**: 228-231 [PMID: 7047032]

7 **Katz MA**. Hyperglycemia-induced hyponatremia--calculation of expected serum sodium depression. *N Engl J Med* 1973; **289**: 843-844 [PMID: 4763428 DOI: 10.1056/NEJM197310182891607]

8 **Kapsner CO**, Tzamaloukas AH. Understanding serum electrolytes. How to avoid mistakes. *Postgrad Med* 1991; **90**: 151-14, 151-14, 161 [PMID: 1749730]

9 **Kitabchi AE**, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care* 2009; **32**: 1335-1343 [PMID: 19564476 DOI: 10.2337/dc09-9032]

10 **SELDIN DW**, TARAIL R. Effect of hypertonic solutions on metabolism and excretion of electrolytes. *Am J Physiol* 1949; **159**: 160-174 [PMID: 15391092]

11 **Gennari FJ**, Kassirer JP. Osmotic diuresis. *N Engl J Med* 1974; **291**: 714-720 [PMID: 4604866 DOI: 10.1056/NEJM197410032911408]

12 **Tzamaloukas AH,** Sun Y, Konstantinov NK, Ing TS, Dorin RI, Malhotra D, Murata GH, Shapiro JI. Principles of quantitative fluid and cation replacement in extreme hyperglycemia. *Cureus* 2013; **5:** e110 [DOI: 10.7759/cureus.110]

13 **Robertson GL.** Thirst and vasopressin. In: Alpern RJ, Hebert SC. Seldin and Giebisch’s The Kidney. Physiology and Pathophysiology. 4th ed. Amsterdam: Elsevier, 2008: 1123-1141

14 **Markowitz GS**, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D'Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. *J Am Soc Nephrol* 2000; **11**: 1439-1448 [PMID: 10906157]

15 **Marples D**, Christensen S, Christensen EI, Ottosen PD, Nielsen S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. *J Clin Invest* 1995; **95**: 1838-1845 [PMID: 7535800 DOI: 10.1172/JCI117863]

16 **Grünfeld JP**, Rossier BC. Lithium nephrotoxicity revisited. *Nat Rev Nephrol* 2009; **5**: 270-276 [PMID: 19384328 DOI: 10.1038/nrneph.2009.43]

17 **Kim GH**, Lee JW, Oh YK, Chang HR, Joo KW, Na KY, Earm JH, Knepper MA, Han JS. Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. *J Am Soc Nephrol* 2004; **15**: 2836-2843 [PMID: 15504936 DOI: 10.1097/01.ASN.0000134476.93376.94]

18 **Stone KA**. Lithium-induced nephrogenic diabetes insipidus. *J Am Board Fam Pract* 1999; **12**: 43-47 [PMID: 10050642 DOI: 10.3122/15572625-12-1-43]

19 **Shaikh BS**, Nicholas GG, Miller FJ. Persistent nephrogenic diabetes insipidus after lithium carbonate. *Ann Intern Med* 1977; **86**: 446-447 [PMID: 848808 DOI: 10.7326/0003-4819-86-4-446]

20 **Gitlin M**. Lithium and the kidney: an updated review. *Drug Saf* 1999; **20**: 231-243 [PMID: 10221853 DOI: 10.2165/00002018-199920030-00004]

21 **Movig KL**, Baumgarten R, Leufkens HG, van Laarhoven JH, Egberts AC. Risk factors for the development of lithium-induced polyuria. *Br J Psychiatry* 2003; **182**: 319-323 [PMID: 12668407 DOI: 10.1192/bjp.182.4.319]

22 **Grandjean EM**, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. *CNS Drugs* 2009; **23**: 397-418 [PMID: 19453201 DOI: 10.2165/00023210-200923050-00004]

23 **Price TR**, Beisswenger PJ. Persistent lithium-induced nephrogenic diabetes insipidus. *Am J Psychiatry* 1978; **135**: 1247-1248 [PMID: 696918]

24 **Rabin EZ**, Garston RG, Weir RV, Posen GA. Persistent nephrogenic diabetes insipidus associated with long-term lithium carbonate treatment. *Can Med Assoc J* 1979; **121**: 194-198 [PMID: 519597]

25 **Cairns SR**, Wolman R, Lewis JG, Thakker R. Persistent nephrogenic diabetes insipidus, hyperparathyroidism, and hypothyroidism after lithium treatment. *Br Med J (Clin Res Ed)* 1985; **290**: 516-517 [PMID: 3918654 DOI: 10.1136/bmj.290.6467.516]

26 **Neithercut WD**, Spooner RJ, Hendry A, Dagg JH. Persistent nephrogenic diabetes insipidus, tubular proteinuria, aminoaciduria, and parathyroid hormone resistance following longterm lithium administration. *Postgrad Med J* 1990; **66**: 479-482 [PMID: 2170960 DOI: 10.1136/pgmj.66.776.479]

27 **Thompson CJ**, France AJ, Baylis PH. Persistent nephrogenic diabetes insipidus following lithium therapy. *Scott Med J* 1997; **42**: 16-17 [PMID: 9226773]

28 **Guirguis AF**, Taylor HC. Nephrogenic diabetes insipidus persisting 57 months after cessation of lithium carbonate therapy: report of a case and review of the literature. *Endocr Pract* 2000; **6**: 324-328 [PMID: 11242610 DOI: 10.4158/EP.7.4.324]

29 [No authors listed]. Hyperosmolar coma due to lithium-induced diabetes insipidus. *Lancet* 1995; **346**: 413-417 [PMID: 7623573]

30 **Sze L**, Ulrich B, Brändle M. Severe hypernatraemia due to nephrogenic diabetes insipidus - a life-threatening side effect of chronic lithium therapy. *Exp Clin Endocrinol Diabetes* 2006; **114**: 596-598 [PMID: 17177143 DOI: 10.1055/s-2006-924124]

31 **Johnson MA**, Ogorman J, Golembiewski GH, Paluzzi MW. Nephrogenic diabetes insipidus secondary to lithium therapy in the postoperative patient: a case report. *Am Surg* 1994; **60**: 836-839 [PMID: 7978676]

32 **Waise A**, Fisken RA. Unsuspected nephrogenic diabetes insipidus. *BMJ* 2001; **323**: 96-97 [PMID: 11451787 DOI: 10.1136/bmj.323.7304.96]

33 **Paw H**, Slingo ME, Tinker M. Late onset nephrogenic diabetes insipidus following cessation of lithium therapy. *Anaesth Intensive Care* 2007; **35**: 278-280 [PMID: 17444321]

34 **Lee RV**, Jampol LM, Brown WV. Nephrogenic diabetes insipidus and lithium intoxication--complications of lithium carbonate therapy. *N Engl J Med* 1971; **284**: 93-94 [PMID: 5538641 DOI: 10.1056/NEJM197101142840209]

35 **Martinez-Maldonado M**, Terrell J. Lithium carbonate-induced nephrogenic diabetes insipidus and glucose intolerance. *Arch Intern Med* 1973; **132**: 881-884 [PMID: 4757260 DOI: 10.1001/archinte.1973.03650120081015]

36 **de Wardener HE.** The Kidney. An Outline of Normal and Abnormal Structure and Function. 2nd ed. London: JA Churchill Ltd, 1961: 45-48

**P-Reviewer:** Fujigaki Y, Paraskevas KI, Taheri S **S-Editor:** Song XX

**L-Editor: E-Editor:**

**Table 1 Serum chemistries and calculated values related to tonicity**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Time | [Glu]mg/dL | [Na]mmol/L | TonicitymOsm/L | [Na]Correctedmmol/L |
| -15 to -2 yr1a | 99.6 ± 22.0 | 141.1 ± 2.7 | 287.6 ± 5.6 | 141.0 ± 2.7 |
| -21 d1 | 235 | 139 | 291.1 | 141.6 |
| -14 d1 | 304 | 141 | 298.9 | 144.3 |
| -3 d1 | 809 | 135 | 314.9 | 146.3 |
| Admission | 1236 | 168 | 404.7 | 186.2 |
| +2 h2 | 1141 | 169 | 401.4 | 185.7 |
| +4 h2 | 982 | 170 | 394.6 | 184.1 |
| +10 h2 | 771 | 165 | 372.8 | 175.7 |
| +14 h2 | 650 | 163 | 362.1 | 171.8 |
| +18 h2 | 611 | 160 | 353.9 | 168.2 |
| +22 h2 | 548 | 165 | 360.4 | 172.2 |
| +24-48 h2 | 233.5 ± 151.7 | 164.0 ± 1.9 | 341.0 ± 9.7 | 166.0 ± 3.3 |
| +48-72 h2 | 176.6 ± 72.3 | 168.0 ± 1.9 | 345.8 ± 7.6 | 169.2 ± 3.0 |
| +72-96 h2 | 151.8 ± 23.0 | 165.3 ± 2.6 | 338.9 ± 4.7 | 166.1 ± 2.1 |
| +96-120 h2 | 185.0 ± 99.0 | 176.5 ± 2.1 | 363.3 ± 1.3 | 177.9 ± 0.5 |
| +120-144 h2 | 131 | 172 | 351.3 | 172.5 |
| +144-168 h2 | 135 | 157 | 321.5 | 157.6 |
| +168-192 h2 | 186.5 ± 139.3 | 158.0 ± 9.9 | 326.4 ± 27.5 | 159.4 ± 12.2 |
| +9-14 d2 | 175.5 ± 53.7 | 146.8 ± 1.8 | 303.5 ± 4.4 | 147.9 ± 1.8 |
| +14-21 d2 | 241.3 ± 55.6 | 143.0 ± 3.9 | 299.4 ± 7.0 | 145.2 ± 3.7 |
| +3 mo2 | 240 | 155 | 323.3 | 157.2 |

1Time before admission; 2Time after onset of treatment; aPeriod of lithium intake; [Glu]: Serum glucose concentration; [Na]: Serum sodium concentration; $\left[Na\right]\_{Corrected}$: Serum sodium concentration corrected to a serum glucose level of 100 mg/dL; Values reported as mean ± SD represent 2-22 measurements.